Aktienanalyse zu China Pharma Holdings Inc (CPHI)CPHIChina Pharma Holdings Inc

China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

China Pharma Holdings Inc is not a good buy right now. The current price is $0.56, which is significantly down from its 52-week high of $19.19, indicating a loss of over 97% from its peak. The RSI is at 35.803, suggesting the stock is oversold, but the overall trend is negative with a year-to-date change of -53.41%. The company has reported consistent net losses, with a net income of -1,458,123 USD in Q2 2026 and a gross margin of only 8.81%. The main risk is its declining revenue and negative earnings, which could further impact its stock price.